78 related articles for article (PubMed ID: 8603604)
1. Antibody to beta3 integrin inhibits osteoclast-mediated bone resorption in the thyroparathyroidectomized rat.
Crippes BA; Engleman VW; Settle SL; Delarco J; Ornberg RL; Helfrich MH; Horton MA; Nickols GA
Endocrinology; 1996 Mar; 137(3):918-24. PubMed ID: 8603604
[TBL] [Abstract][Full Text] [Related]
2. Contortrostatin, a homodimeric snake venom disintegrin, is a potent inhibitor of osteoclast attachment.
Mercer B; Markland F; Minkin C
J Bone Miner Res; 1998 Mar; 13(3):409-14. PubMed ID: 9525341
[TBL] [Abstract][Full Text] [Related]
3. Integrin subunit beta3 plays a crucial role in the movement of osteoclasts from the periosteum to the bone surface.
Holt I; Marshall MJ
J Cell Physiol; 1998 Apr; 175(1):1-9. PubMed ID: 9491775
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of osteoclastic bone resorption in vivo by echistatin, an "arginyl-glycyl-aspartyl" (RGD)-containing protein.
Fisher JE; Caulfield MP; Sato M; Quartuccio HA; Gould RJ; Garsky VM; Rodan GA; Rosenblatt M
Endocrinology; 1993 Mar; 132(3):1411-3. PubMed ID: 8440195
[TBL] [Abstract][Full Text] [Related]
5. In vivo administration of 1,25-dihydroxyvitamin D3 suppresses the expression of RANKL mRNA in bone of thyroparathyroidectomized rats constantly infused with PTH.
Ueno Y; Shinki T; Nagai Y; Murayama H; Fujii K; Suda T
J Cell Biochem; 2003 Oct; 90(2):267-77. PubMed ID: 14505343
[TBL] [Abstract][Full Text] [Related]
6. Antagonism of the osteoclast vitronectin receptor with an orally active nonpeptide inhibitor prevents cancellous bone loss in the ovariectomized rat.
Lark MW; Stroup GB; Dodds RA; Kapadia R; Hoffman SJ; Hwang SM; James IE; Lechowska B; Liang X; Rieman DJ; Salyers KL; Ward K; Smith BR; Miller WH; Huffman WF; Gowen M
J Bone Miner Res; 2001 Feb; 16(2):319-27. PubMed ID: 11204432
[TBL] [Abstract][Full Text] [Related]
7. A Glanzmann's mutation in beta 3 integrin specifically impairs osteoclast function.
Feng X; Novack DV; Faccio R; Ory DS; Aya K; Boyer MI; McHugh KP; Ross FP; Teitelbaum SL
J Clin Invest; 2001 May; 107(9):1137-44. PubMed ID: 11342577
[TBL] [Abstract][Full Text] [Related]
8. Histomorphometric evidence for echistatin inhibition of bone resorption in mice with secondary hyperparathyroidism.
Masarachia P; Yamamoto M; Leu CT; Rodan G; Duong L
Endocrinology; 1998 Mar; 139(3):1401-10. PubMed ID: 9492077
[TBL] [Abstract][Full Text] [Related]
9. 17beta-estradiol downregulates beta3-integrin expression in differentiating and mature human osteoclasts.
Saintier D; Burde MA; Rey JM; Maudelonde T; de Vernejoul MC; Cohen-Solal ME
J Cell Physiol; 2004 Feb; 198(2):269-76. PubMed ID: 14603529
[TBL] [Abstract][Full Text] [Related]
10. Structure-activity studies of the s-echistatin inhibition of bone resorption.
Sato M; Garsky V; Majeska RJ; Einhorn TA; Murray J; Tashjian AH; Gould RJ
J Bone Miner Res; 1994 Sep; 9(9):1441-9. PubMed ID: 7817829
[TBL] [Abstract][Full Text] [Related]
11. A naturally occurring point mutation in the beta3 integrin MIDAS-like domain affects differently alphavbeta3 and alphaIIIbbeta3 receptor function.
Morel-Kopp MC; Melchior C; Chen P; Ammerlaan W; Lecompte T; Kaplan C; Kieffer N
Thromb Haemost; 2001 Dec; 86(6):1425-34. PubMed ID: 11776310
[TBL] [Abstract][Full Text] [Related]
12. Mice lacking beta3 integrins are osteosclerotic because of dysfunctional osteoclasts.
McHugh KP; Hodivala-Dilke K; Zheng MH; Namba N; Lam J; Novack D; Feng X; Ross FP; Hynes RO; Teitelbaum SL
J Clin Invest; 2000 Feb; 105(4):433-40. PubMed ID: 10683372
[TBL] [Abstract][Full Text] [Related]
13. Structural determinants of calcium signaling by RGD peptides in rat osteoclasts: integrin-dependent and -independent actions.
Shankar G; Gadek TR; Burdick DJ; Davison I; Mason WT; Horton MA
Exp Cell Res; 1995 Aug; 219(2):364-71. PubMed ID: 7543851
[TBL] [Abstract][Full Text] [Related]
14. The ability of statins to inhibit bone resorption is directly related to their inhibitory effect on HMG-CoA reductase activity.
Staal A; Frith JC; French MH; Swartz J; Güngör T; Harrity TW; Tamasi J; Rogers MJ; Feyen JH
J Bone Miner Res; 2003 Jan; 18(1):88-96. PubMed ID: 12510809
[TBL] [Abstract][Full Text] [Related]
15. Peptide aldehyde inhibitors of cathepsin K inhibit bone resorption both in vitro and in vivo.
Votta BJ; Levy MA; Badger A; Bradbeer J; Dodds RA; James IE; Thompson S; Bossard MJ; Carr T; Connor JR; Tomaszek TA; Szewczuk L; Drake FH; Veber DF; Gowen M
J Bone Miner Res; 1997 Sep; 12(9):1396-406. PubMed ID: 9286755
[TBL] [Abstract][Full Text] [Related]
16. [Effects of bisphosphonates on vitamin A-induced bone resorption in thyroparathyroidectomized rat].
Gen M
Nihon Seikeigeka Gakkai Zasshi; 1995 Nov; 69(11):1193-207. PubMed ID: 8568374
[TBL] [Abstract][Full Text] [Related]
17. Design and characterization of orally active Arg-Gly-Asp peptidomimetic vitronectin receptor antagonist SB 265123 for prevention of bone loss in osteoporosis.
Lark MW; Stroup GB; Hwang SM; James IE; Rieman DJ; Drake FH; Bradbeer JN; Mathur A; Erhard KF; Newlander KA; Ross ST; Salyers KL; Smith BR; Miller WH; Huffman WF; Gowen M
J Pharmacol Exp Ther; 1999 Nov; 291(2):612-7. PubMed ID: 10525079
[TBL] [Abstract][Full Text] [Related]
18. Echistatin is a potent inhibitor of bone resorption in culture.
Sato M; Sardana MK; Grasser WA; Garsky VM; Murray JM; Gould RJ
J Cell Biol; 1990 Oct; 111(4):1713-23. PubMed ID: 2211834
[TBL] [Abstract][Full Text] [Related]
19. Beta3 tyrosine phosphorylation in alphaIIbbeta3 (platelet membrane GP IIb-IIIa) outside-in integrin signaling.
Phillips DR; Nannizzi-Alaimo L; Prasad KS
Thromb Haemost; 2001 Jul; 86(1):246-58. PubMed ID: 11487013
[TBL] [Abstract][Full Text] [Related]
20. Extracellular calcium regulates the adhesion and migration of osteoclasts via integrin α
Xiang B; Liu Y; Zhao W; Zhao H; Yu H
Cell Biol Int; 2019 Oct; 43(10):1125-1136. PubMed ID: 30022569
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
